Human monoclonal antibodies specific for CD22
Disclosed herein are isolated human monoclonal antibodies that specifically bind human CD22 with a dissociation constant (K d ) of 25 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect human CD22 in a sample. In some cases, CD22 is soluble CD22. Methods of diagnosing a B-cell malignancy, or confirming a B-cell malignancy diagnosis, are disclosed herein that utilize these antibodies. Methods of treating a subject with a B-cell malignancy are also disclosed.
1. A method of treating a subject with a CD22-expressing B-cell malignancy, comprising administering to the subject a therapeutically effective amount of a monoclonal antibody that specifically binds human CD22 and is conjugated to an agent that inhibits growth of malignant B cells or kills malignant B cells in the subject, wherein the antibody comprises:
a heavy chain or portion thereof, which comprises an amino acid sequence comprising residues 26-35 of SEQ ID NO: 3, residues 53-61 of SEQ ID NO: 3 and residues 100-113 of SEQ ID NO: 3; and
a light chain or portion thereof, which comprises an amino acid sequence comprising residues 27-32 of SEQ ID NO: 4, residues 50-52 of SEQ ID NO: 4 and residues 89-97 of SEQ ID NO: 4,
wherein the therapeutically effective amount of the monoclonal antibody conjugated to the agent is an amount that inhibits growth of malignant B cells or kills malignant B cells in the subject, thereby treating the subject.
2. The method of claim 1 , wherein the agent is a toxin.
3. The method of claim 2 , wherein the agent is a Pseudomonas exotoxin.
4. The method of claim 1 , wherein the antibody comprises a Fab, scFv, or IgG antibody.
5. The method of claim 4 , wherein the antibody comprises a scFv.
6. The method of claim 1 , wherein the CD22-expressing B-cell malignancy is non-Hodgkin's lymphoma, hairy cell leukemia or chronic lymphocytic leukemia.
7. A method of treating a CD22-expressing B-cell malignancy in a subject, comprising administering to the subject a therapeutically effective amount of an immunoconjugate comprising a monoclonal antibody that specifically binds human CD22 and an effector molecule that inhibits growth of malignant B cells or kills malignant B cells in the subject, wherein the antibody comprises:
a heavy chain or portion thereof, which comprises an amino acid sequence comprising residues 26-35 of SEQ ID NO: 3, residues 53-61 of SEQ ID NO: 3 and residues 100-113 of SEQ ID NO: 3: and
a light chain or portion thereof, which comprises an amino acid sequence comprising residues 27-32 of SEQ ID NO: 4, residues 50-52 of SEQ ID NO: 4 and residues 89-97 of SEQ ID NO: 4,
wherein the therapeutically effective amount of the immunoconjugate is an amount sufficient to inhibit growth of malignant B cells or kill malignant B cells in the subject, thereby treating the subject.
8. The method of claim 7 , wherein the effector molecule comprises a toxin.
9. The method of claim 8 , wherein the effector molecule is a Pseudomonas exotoxin.
10. The method of claim 7 , wherein the antibody comprises a Fab, scFv, or IgG antibody.
11. The method of claim 10 , wherein the antibody comprises a scFv.
12. The method of claim 7 , wherein the CD22-expressing B-cell malignancy is non-Hodgkin's lymphoma, hairy cell leukemia or chronic lymphocytic leukemia.
13. A method of determining if a subject has a CD22-expressing B-cell malignancy, or confirming a diagnosis of a CD22-expressing B-cell malignancy in a subject, comprising:
contacting a sample from the subject with a monoclonal antibody that specifically binds human CD22, the antibody comprising
a heavy chain or portion thereof, which comprises an amino acid sequence comprising residues 26-35 of SEQ ID NO: 3, residues 53-61 of SEQ ID NO: 3 and residues 100-113 of SEQ ID NO: 3, and
a light chain or portion thereof, which comprises an amino acid sequence comprising residues 27-32 of SEQ ID NO: 4, residues 50-52 of SEQ ID NO: 4 and residues 89-97 of SEQ ID NO: 4;
detecting binding of the antibody to CD22 in the sample; and
determining that the subject has a CD22-expressing B-cell malignancy, or confirming the diagnosis of the CD22-expressing B-cell malignancy in the subject, if an increase is detected in the binding of the antibody to CD22 in the sample as compared to the binding of the antibody to a control sample.
14. The method of claim 13 , wherein the monoclonal antibody is directly labeled.